You are here

Correcting Aberrant Splicing of the Human CD22 Gene

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA177067-01A1
Agency Tracking Number: R43CA177067
Amount: $225,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
4519 GRETNA ST
BETHESDA, MD 20814-3956
United States
DUNS: 145949066
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 LLOYD MITCHELL
 (301) 503-1202
 lgm@retrotherapy.biz
Business Contact
 LLOYD MITCHELL
Phone: (240) 597-1967
Email: lgm@retrotherapy.biz
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): B-precursor acute lymphoblastic leukemia (BPL) is the most common form of cancer in children and adolescents. This project addresses an urgent and unmet need for the treatment of aggressive, treatment refractory BPL. Two recent studies have found a deletion of CD22 exon 12 (CD22?E12) in primary leukemic cells in the vast majority of pediatric patients with poor prognosis, newly diagnosed, or relapsed BPL. RT-PCR analysis of primary leukemic cells in matched pair diagnosis vs. induction failure specimens, and diagnosis vs. 1st bone marrow relapse specimens provided direct evidence that the CD22?E12 genetic defect is detectable at the time of initial diagnosis in therapy-refractory pediatric ALL patients. Preliminary studies support the hypothesis that correction of CD22?E12 results in the loss of self-renewal capacity and significantly reduces the clonogenicity of leukemic cells. We intend to develop the therapeutic potential of an RNA technology that corrects expression of

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government